FDA Expands Eli Lilly's Mounjaro Approval to Cut Heart Attack and Stroke Risk

Indianapolis, Friday, 28 August 2026.
The FDA approved Eli Lilly’s Mounjaro to reduce major cardiovascular risks in adults with type 2 diabetes after trials showed an 8% lower risk of events compared to Trulicity.